Archive for: Drug Pricing

  • ORIGINAL ANALYSIS

  • PDF DOWNLOAD

  • EXTERNAL LINK

  • POST

Insight: original analysis

McDermottPlus Check-Up: December 7, 2018

This Week’s Diagnosis: Memorial services for President George H.W. Bush were held this week in Washington, DC and Texas. No agreement has been reached on border wall funding, which means Members may be here through at least December 21.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: November 30, 2018

This Week’s Diagnoses: Welcome back! Members are back in town for a sprint to the finish. Controversy over the House Democratic leadership elections fizzled, with the same faces in the top three positions.

ORIGINAL ANALYSIS

Insight: original analysis

Election Results Bring Change in Health Priorities

Democrats will take control of the House of Representatives in January 2019. Republicans will retain control of the Senate, widening their margin slightly. Split control of Congress will have important consequences for healthcare policy.  This article takes a closer look at how the election is likely to impact the health policy agenda.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: October 26, 2018

This Week’s Diagnosis: The Administration remains active with the issuance of several new guidance documents, the drug pricing announcement and the President (finally) signing the bipartisan opioid legislation (HR 6).

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: October 19, 2018

This Week’s Diagnoses: All eyes are on the midterm election, now less than three weeks away.  The House and Senate are out; the Administration continues to release health-related regulations and announcements.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: September 28, 2018

This Week’s Diagnosis: Consideration of the Kavanaugh nomination dominated airtime in the Senate this week, but the House stayed on-task, pushing through a number of health-related bills.

ORIGINAL ANALYSIS

Insight: original analysis

Oklahoma Is the Place to Be . . . Especially for Value-Based Contracting

This article—the latest in a McDermott+Consulting series investigating the president’s drug pricing plans—takes a closer look at Oklahoma’s recently approved State Plan Amendment that allows Oklahoma to negotiate value-based contracts with drug makers for individuals covered by the state’s Medicaid plan.

ORIGINAL ANALYSIS

Insight: original analysis

White House Builds Momentum for Drug Price Controls

On May 11, 2018, President Trump released the American Patients First Blueprint, a plan to lower drug prices and reduce beneficiary out-of-pocket spending on drugs in the Medicare program.

ORIGINAL ANALYSIS

Insight: original analysis

White House Swings for Fences with FY 2019 Drug Pricing Proposals

Since the run-up to the 2016 presidential election, Donald Trump has stated his interest in controlling and lowering the high cost of prescription drugs. Until recently his administration had released limited details on possible ways to do so.

ORIGINAL ANALYSIS

beakernav X1E2BFA62-BFCE-43C1-B777-27E3E5216018medical bagoriginal analysis +external linkpdf downloadstethoscope